What factors did the committee consider when assessing the cost-effectiveness of beta-blockers for HF-REF and AF?
When assessing the cost-effectiveness of beta-blockers for HF-REF and AF, the committee considered the trade-off between net clinical effects and costs, the unit costs of beta-blockers, the costs for heart-failure related hospitalisation and stroke, the cost of low dose (2.5mg) Nebivolol, the time required for up-titration appointments, the HRG codes for heart failure hospitalisation, and the cost of stroke events. Additionally, the committee only reviewed the evidence in the HF-REF and AF population and not the HF-PEF and AF population, due to a lack of prognostic evidence for the use of beta-blockers in HF-PEF. 